A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults

Science Translational Medicine

Volumn 6, Issue 234, 2014, Pages

  Bart, Stephan A ^a   Hohenboken, Matthew ^b   Della Cioppa, Giovanni ^b   Narasimhan, Vas ^b   Dormitzer, Philip R ^b   Kanesa thasan, Niranjan ^b  

^a Accelovance Inc   (United States)

^b Novartis Vaccines Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; PANDEMIC INFLUENZA A H7N9 VACCINE; UNCLASSIFIED DRUG; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

ADULT; AGED; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CELL CULTURE; CHINA; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; INFESTATION; INFLUENZA VIRUS A H7N9; INJECTION SITE INDURATION; INJECTION SITE PAIN; LOSS OF APPETITE; MALAISE; MALE; MICRONEUTRALIZATION ASSAY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SERODIAGNOSIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VACCINE PRODUCTION; VOMITING; CLINICAL TRIAL; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED;

ADULT; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE;

EID: 84899802646     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008761     Document Type: Article

References (51)

1. J. Shi, J. Xie, Z. He, Y. Hu, Y. He, Q. Huang, B. Leng, W. He, Y. Sheng, F. Li, Y. Song, C. Bai, Y. Gu, Z. Jie, A detailed epidemiological and clinical description of 6 human cases of avian-origin influenza A (H7N9) virus infection in Shanghai. PLOS One 8, e77651 (2013).
2. World Health Organization, www.who.int/influenza/human-animal-interface/ influenza-h7n9/Data-Reports/en/index.html.
3. M. F. Boni, N. V. Chau, N. Dong, S. Todd, N. T. Nhat, E. de Bruin, J. van Beek, N. T. Hien, C. P. Simmons, J. Farrar, M. Koopmans, Population-level antibody estimates to novel influenza A/H7N9. J. Infect. Dis. 208, 554-558 (2013).
4. R. Gao, B. Cao, Y. Hu, Z. Feng, D. Wang, W. Hu, J. Chen, Z. Jie, H. Qiu, K. Xu, X. Xu, H. Lu, W. Zhu, Z. Gao, N. Xiang, Y. Shen, Z. He, Y. Gu, Z. Zhang, Y. Yang, X. Zhao, L. Zhou, X. Li, S. Zou, Y. Zhang, L. Yang, J. Guo, J. Dong, Q. Li, L. Dong, Y. Zhu, T. Bai, S. Wang, P. Hao, W. Yang, Y. Zhang, J. Han, H. Yu, D. Li, G. F. Gao, G. Wu, Y. Wang, Z. Yuan, Y. Shu, Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368, 1888-1897 (2013).
5. T. M. Uyeki, N. J. Cox, Global concerns regarding novel influenza A (H7N9) virus infections. N. Engl. J. Med. 368, 1862-1864 (2013).
6. X. Qi, Y. H. Qian, C. J. Bao, X. L. Guo, L. B. Cui, F. Y. Tang, H. Ji, Y. Huang, P. Q. Cai, B. Lu, K. Xu, C. Shi, F. C. Zhu, M. H. Zhou, H. Wang, Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: Epidemiological investigation. BMJ 347, f4752 (2013).
7. Q. Zhang, J. Shi, G. Deng, J. Guo, X. Zeng, X. He, H. Kong, C. Gu, X. Li, J. Liu, G. Wang, Y. Chen, L. Liu, L. Liang, Y. Li, J. Fan, J. Wang, W. Li, L. Guan, Q. Li, H. Yang, P. Chen, L. Jiang, Y. Guan, X. Xin, Y. Jiang, G. Tian, X. Wang, C. Qiao, C. Li, Z. Bu, H. Chen, H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341, 410-414 (2013).
8. P. R. Dormitzer, P. Suphaphiphat, D. G. Gibson, D. E. Wentworth, T. B. Stockwell, M. A. Algire, N. Alperovich, M. Barro, D. M. Brown, S. Craig, B. M. Dattilo, E. A. Denisova, I. De Souza, M. Eickmann, V. G. Dugan, A. Ferrari, R. C. Gomila, L. Han, C. Judge, S. Mane, M. Matrosovich, C. Merryman, G. Palladino, G. A. Palmer, T. Spencer, T. Strecker, H. Trusheim, J. Uhlendorff, Y. Wen, A. C. Yee, J. Zaveri, B. Zhou, S. Becker, A. Donabedian, P. W. Mason, J. I. Glass, R. Rappuoli, J. C. Venter, Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci. Transl. Med. 5, 185ra168 (2013).
9. Y. Genzel, U. Reichl, Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 8, 1681-1692 (2009).
10. W. P. Glezen, Cell-culture-derived influenza vaccine production. Lancet 377, 698-700 (2011).
11. W. Keitel, N. Groth, M. Lattanzi, M. Praus, A. K. Hilbert, A. Borkowski, T. F. Tsai, Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28, 840-848 (2010).
12. World Health Organization, Pandemic influenza A (H1N1) 2009 virus vaccine - Conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. Wkly. Epidemiol. Rec. 84, 505-516 (2009).
13. D. T. O'Hagan, G. S. Ott, G. V. Nest, R. Rappuoli, G. D. Giudice, The history of MF59® adjuvant: A phoenix that arose from the ashes. Expert Rev. Vaccines 12, 13-30 (2013).
14. T. W. Clark, M. Pareek, K. Hoschler, H. Dillon, K. G. Nicholson, N. Groth, I. Stephenson, Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361, 2424-2435 (2009).
15. S. Black, G. Della Cioppa, A. Malfroot, P. Nacci, U. Nicolay, M. Pellegrini, E. Sokal, A. Vertruyen, Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis. Vaccine 28, 7331-7336 (2010).
16. A. Podda, G. Del Giudice, MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2, 197-203 (2003).
17. T. F. Tsai, A. Crucitti, P. Nacci, U. Nicolay, G. Della Cioppa, J. Ferguson, R. Clemens, Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand. J. Infect. Dis. 43, 702-706 (2011).
18. S. Black, U. Nicolay, T. Vesikari, M. Knuf, G. Del Giudice, G. Della Cioppa, T. Tsai, R. Clemens, R. Rappuoli, Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30, 1081-1085 (2011).
19. S. Ng, V. J. Fang, D. K. Ip, K. H. Chan, G. M. Leung, J. S. Peiris, B. J. Cowling, Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J. Infect. Dis. 208, 1320-1324 (2013).
20. K. G. Nicholson, A. E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma, M. C. Zambon, Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943 (2001).
21. R. L. Atmar, W. A. Keitel, S. M. Patel, J. M. Katz, D. She, H. El Sahly, J. Pompey, T. R. Cate, R. B. Couch, Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43, 1135-1142 (2006).
22. R. B. Couch, W. K. Decker, B. Utama, R. L. Atmar, D. Niño, J. Q. Feng, M. M. Halpert, G. M. Air, Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLOS One 7, e50830 (2012).
23. D. I. Bernstein, K. M. Edwards, C. L. Dekker, R. Belshe, H. K. Talbot, I. L. Graham, D. L. Noah, F. He, H. Hill, Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197, 667-675 (2008).
24. L. Guo, X. Zhang, L. Ren, X. Yu, L. Chen, H. Zhou, X. Gao, Z. Teng, J. Li, J. Hu, C. Wu, X. Xiao, Y. Zhu, Q. Wang, X. Pang, Q. Jin, F. Wu, J. Wang, Human antibody responses to avian influenza A(H7N9) virus, 2013. Emerg. Infect. Dis. 20, 192-200 (2014).
25. S. De Donato, D. Granoff, M. Minutello, G. Lecchi, M. Faccini, M. Agnello, F. Senatore, P. Verweij, B. Fritzell, A. Podda, Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17, 3094-3101 (1999).
26. R. Gasparini, T. Pozzi, E. Montomoli, E. Fragapane, F. Senatore, M. Minutello, A. Podda, Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 17, 135-140 (2001).
27. S. Khurana, W. Chearwae, F. Castellino, J. Manischewitz, L. R. King, A. Honorkiewicz, M. T. Rock, K. M. Edwards, G. Del Giudice, R. Rappuoli, H. Golding, Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra15 (2010).
28. J. L. Bresson, C. Perronne, O. Launay, C. Gerdil, M. Saville, J. Wood, K. Höschler, M. C. Zambon, Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367, 1657-1664 (2006).
29. A. Banzhoff, M. Pellegrini, G. Del Giudice, E. Fragapane, N. Groth, A. Podda, MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir. Viruses 2, 243-249 (2008).
30. L. F. Fries, G. E. Smith, G. M. Glenn, A recombinant viruslike particle influenza A (H7N9) vaccine. N. Engl. J. Med. 369, 2564-2566 (2013).
31. A. Banzhoff, R. Gasparini, F. Laghi-Pasini, T. Staniscia, P. Durando, E. Montomoli, P. Capecchi, P. di Giovanni, L. Sticchi, C. Gentile, A. K. Hilbert, V. Brauer, S. Tilman, A. Podda, MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLOS One 4, e4384 (2009).
32. T. Vesikari, A. Karvonen, S. Tilman, A. Borkowski, E. Montomoli, A. Banzhoff, R. Clemens, Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126, e762-e770 (2010).
33. + memory B cells. PLOS One 3, e3942 (2008).
34. B. L. Lu, R. G. Webster, V. S. Hinshaw, Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. Infect. Immun. 38, 530-535 (1982).
35. A. Zhang, Y. Huang, D. Tian, E. Lau, Y. Wan, X. Liu, Y. Dong, Z. Song, X. Zhang, J. Zhang, M. Bao, M. Zhou, S. Yuan, J. Sun, Z. Zhu, Y. Hu, L. Chen, C. Leung, J. Wu, Z. Zhang, X. Zhang, J. Peiris, J. Xu, Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro Surveill. 18, 20657 (2013).
36. F. Krammer, R. J. Cox, The emergence of H7N9 viruses: A chance to redefine correlates of protection for influenza virus vaccines. Expert Rev. Vaccines 12, 1369-1372 (2013).
37. I. Stephenson, R. Bugarini, K. G. Nicholson, A. Podda, J. M. Wood, M. C. Zambon, J. M. Katz, Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J. Infect. Dis. 191, 1210-1215 (2005).
38. K. Levie, I. Leroux-Roels, K. Hoppenbrouwers, A. D. Kervyn, C. Vandermeulen, S. Forgus, G. Leroux-Roels, S. Pichon, I. Kusters, An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198, 642-649 (2008).
39. I. Leroux-Roels, A. Borkowski, T. Vanwolleghem, M. Dramé, F. Clement, E. Hons, J. M. Devaster, G. Leroux-Roels, Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370, 580-589 (2007).
40. C. Hatz, J. P. Cramer, A. Vertruyen, T. F. Schwarz, F. von Sonnenburg, A. Borkowski, M. Lattanzi, A. K. Hilbert, G. D. Cioppa, G. Leroux-Roels, A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 30, 4820-4827 (2012).
41. H. Fukase, H. Furuie, Y. Yasuda, R. Komatsu, K. Matsushita, T. Minami, Y. Suehiro, H. Yotsuyanagi, H. Kusadokoro, H. Sawata, N. Nakura, M. Lattanzi, Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine 30, 5030-5037 (2012).
42. S. L. Block, J. Falloon, J. A. Hirschfield, L. R. Krilov, F. Dubovsky, T. Yi, R. B. Belshe, Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 31, 745-751 (2012).
43. H. J. Cheong, J. Y. Song, J. Y. Heo, J. Y. Noh, W. S. Choi, D. W. Park, S. H. Wie, W. J. Kim, Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin. Vaccine Immunol. 18, 1358-1364 (2011).
44. M. Tizzoni, P. Bajardi, C. Poletto, J. Ramasco, D. Balcan, B. Gonçalves, N. Perra, V. Colizza, A. Vespignani, Real-time numerical forecast of global epidemic spreading: Case study of 2009 A/H1N1pdm. BMC Med. 10, 165 (2012).
45. F. Roman, T. Vaman, B. Gerlach, A. Markendorf, P. Gillard, J. M. Devaster, Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial. Vaccine 28, 1740-1745 (2010).
46. J. J. Treanor, J. D. Campbell, K. M. Zangwill, T. Rowe, M. Wolff, Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354, 1343-1351 (2006).
47. M. Pellegrini, U. Nicolay, K. Lindert, N. Groth, G. Della Cioppa, MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine 27, 6959-6965 (2009).
48. R. J. Cox, Correlates of protection to influenza virus, where do we go from here? Hum. Vaccin. Immunother. 9, 405-408 (2013).
49. R. J. Cox, D. Major, S. Hauge, A. S. Madhun, K. A. Brokstad, M. Kuhne, J. Smith, F. R. Vogel, M. Zambon, L. R. Haaheim, J. Wood, A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir. Viruses 3, 107-117 (2009).
50. I. Stephenson, A. Heath, D. Major, R. W. Newman, K. Hoschler, W. Junzi, J. M. Katz, J. P. Weir, M. C. Zambon, J. M. Wood, Reproducibility of serologic assays for influenza virus A (H5N1). Emerg. Infect. Dis. 15, 1252-1259 (2009).
51. T. Rowe, R. A. Abernathy, J. Hu-Primmer, W. W. Thompson, X. Lu, W. Lim, K. Fukuda, N. J. Cox, J. M. Katz, Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37, 937-943 (1999).